Anna Flávia Matos Soares
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Flávia Matos Soares has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Bruna Gomes Pegorelli
Laboratório de Controle de Qualidade - Programa de Pós-graduação em Ciências Farmacêuticas-CiPharma, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto. Brazil
1 shared publication - Bruna de Carvalho Mapa
Quality Control Laboratory–Pharmaceutical Sciences Post-graduate Program, Pharmacy School, Federal University of Ouro Preto, Ouro Preto 35400-000, Brazil
1 shared publication - Carolina Carvalho Della Croce
Laboratório de Controle de Qualidade - Programa de Pós-graduação em Ciências Farmacêuticas-CiPharma, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto. Brazil
1 shared publication - Jacqueline de Souza
Federal University of Ouro Preto, UFOP
1 shared publication - Lara Maria Lopes de Castro
Laboratório de Controle de Qualidade - Programa de Pós-graduação em Ciências Farmacêuticas-CiPharma, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto. Brazil
1 shared publication - Neila Márcia Silva-Barcellos
Docente/Escola de Farmácia de Ouro Preto, Universidade Federal de Ouro Preto (UFOP), Ouro Preto, Minas Gerais
1 shared publication
Latest Publications
- Open Access
- 19 June 2020
- Published by Bentham Science Publishers Ltd. in Current Drug Research Reviews
- Vol. 12 (1) , 52-62
The Evaluation of Valsartan Biopharmaceutics Properties
Background: Solubility, intestinal permeability and dissolution are the main factors that govern the rate and extent of drugs absorption and are directly related to bioavailability. Biopharmaceutics Classification System (BCS) is an important tool which uses in vitro results for comparison with bioavailability in vivo (biowaiver). Valsartan is widely used in the treatment of hypertension and shows different BCS classification in the literature (BCS class II or III). Objective: This work proposes the study of valsartan biopharmaceutics properties and its BCS classification. Methods: High Performance Liquid Chromatography (HPLC) method was developed and validated to quantify the drug in buffers pH 1.2, 4.5 and 6.8 respectively. Valsartan solubility was determined in these three different media using shake flask method and intrinsic dissolution rate. Evaluation of dissolution profile from coated tablets was conducted. Results: The low solubility (pH 1.2 and 4.5) and high solubility (pH 6.8) were observed for both solubility methods. Permeability data reported from the literature showed that valsartan is a low permeability drug. Valsartan presented the rapid release profile only in pH 6.8. Conclusion: We defined that valsartan is a class IV drug, in disagreement with what has been published so far. It is important to emphasize that the conditions considered here are indicated to define the biopharmaceutics classification by regulatory agencies.
- 19 June 2020
- Published by Bentham Science Publishers Ltd. in Current Drug Research Reviews
- Vol. 12 (1) , 52-62
Open AccessThe Evaluation of Valsartan Biopharmaceutics Properties
Background: Solubility, intestinal permeability and dissolution are the main factors that govern the rate and extent of drugs absorption and are directly related to bioavailability. Biopharmaceutics Classification System (BCS) is an important tool which uses in vitro results for comparison with bioavailability in vivo (biowaiver). Valsartan is widely used in the treatment of hypertension and shows different BCS classification in the literature (BCS class II or III). Objective: This work proposes the study of valsartan biopharmaceutics properties and its BCS classification. Methods: High Performance Liquid Chromatography (HPLC) method was developed and validated to quantify the drug in buffers pH 1.2, 4.5 and 6.8 respectively. Valsartan solubility was determined in these three different media using shake flask method and intrinsic dissolution rate. Evaluation of dissolution profile from coated tablets was conducted. Results: The low solubility (pH 1.2 and 4.5) and high solubility (pH 6.8) were observed for both solubility methods. Permeability data reported from the literature showed that valsartan is a low permeability drug. Valsartan presented the rapid release profile only in pH 6.8. Conclusion: We defined that valsartan is a class IV drug, in disagreement with what has been published so far. It is important to emphasize that the conditions considered here are indicated to define the biopharmaceutics classification by regulatory agencies.